Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.

Journal of viral hepatitis - 1 Nov 2015

Hedskog C, Dvory-Sobol H, Gontcharova V, Martin R, Ouyang W, Han B, Gane E J, Brainard D, Hyland R H, Miller M D, Mo H, Svarovskaia E

Abstract excerpt

Clinical phase II/III studies of the nucleotide analogue HCV NS5B inhibitor sofosbuvir (SOF) have demonstrated high efficacy in HCV-infected patients in combination therapy. To date, resistance to SOF (S282T in NS5B) has rarely been detected in patients. In this study, we investigated the evolution of S282T viral variants detected in one HCV genotype 2b-infected patient who relapsed following 12 weeks of SOF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Longitudinal Studies

Share to Recurrence

Share to Sofosbuvir

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 25784085
DOI: 10.1111/jvh.12405

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.PMID 25784085Read ↗

Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.Semantic proximity Read ↗

Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.Semantic proximity Read ↗

Evidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy.Semantic proximity Read ↗

Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?Semantic proximity Read ↗

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.Semantic proximity Read ↗

Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.Semantic proximity Read ↗

Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?Semantic proximity Read ↗

Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.Semantic proximity Read ↗

Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients.Semantic proximity Read ↗

Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.Semantic proximity Read ↗

Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.Semantic proximity Read ↗

Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.